NICE TAs

11/10/2021

TA719: Secukinumab for treating non-radiographic axial spondyloarthritis

11/10/2021

TA700: Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)

11/10/2021

TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

11/10/2021

TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement

11/10/2021

TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma

11/10/2021

TA723: Bimekizumab for treating moderate to severe plaque psoriasis

11/10/2021

TA721: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer

11/10/2021

TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer

11/10/2021

TA725: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

11/10/2021

TA728: Midostaurin for treating advanced systemic mastocytosis

11/10/2021

TA729: Sapropterin for treating hyperphenylalaninaemia in phenylketonuria

11/10/2021

TA730: Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)

11/10/2021

TA731: Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)

11/10/2021

TA732: Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)

11/10/2021

TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people

16/12/2020

TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma

25/11/2020

TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

25/11/2020

TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

18/11/2020

TA656: Siponimod for treating secondary progressive multiple sclerosis

18/11/2020

TA657: Carfilzomib for previously treated multiple myeloma